A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect
of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid
therapy in patients with moderate to severe asthma with elevated sputum neutrophils.